Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGTNASDAQ:OGINASDAQ:RLAYNASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$5.02+2.2%$5.97$3.72▼$12.61$571.56M1.671.26 million shs1.46 million shsOGIOrganigram$1.14+1.8%$1.06$0.85▼$2.17$143.95M1.1747,336 shs232,258 shsRLAYRelay Therapeutics$3.10-4.9%$2.98$1.78▼$10.72$525.52M1.71.99 million shs1.54 million shsVALNValneva$6.45-1.8%$6.87$3.62▼$9.50$539.45M1.8536,673 shs22,384 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences+5.82%+14.19%-24.23%-45.02%-18.44%OGIOrganigram-3.45%+12.00%+8.74%-26.80%-39.78%RLAYRelay Therapeutics+1.87%+18.55%+19.85%-29.44%-48.82%VALNValneva-6.61%-0.90%-9.50%+32.73%-14.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOGTCogent Biosciences2.3624 of 5 stars4.40.00.00.03.90.00.6OGIOrganigram0.835 of 5 stars0.03.00.00.02.50.01.3RLAYRelay Therapeutics2.0158 of 5 stars3.41.00.00.01.92.50.6VALNValneva2.5459 of 5 stars3.55.00.00.02.50.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.75Moderate Buy$14.43187.42% UpsideOGIOrganigram 3.00BuyN/AN/ARLAYRelay Therapeutics 2.82Moderate Buy$18.36492.38% UpsideVALNValneva 3.00Buy$16.00148.06% UpsideCurrent Analyst Ratings BreakdownLatest OGI, COGT, RLAY, and VALN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025RLAYRelay TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$4.004/15/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/9/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/31/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/24/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $15.003/21/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/7/2025COGTCogent BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/7/2025COGTCogent BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$17.003/7/2025RLAYRelay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/28/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.002/27/2025COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$2.30 per shareN/AOGIOrganigram$166.12M0.87N/AN/A$1.83 per share0.62RLAYRelay Therapeutics$10.01M52.52N/AN/A$5.90 per share0.53VALNValneva$169.58M3.18N/AN/A$2.00 per share3.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$192.41M-$1.94N/AN/AN/AN/A-112.55%-60.44%5/6/2025 (Estimated)OGIOrganigram-$33.39M-$0.38N/AN/AN/A-31.69%-8.59%-6.54%5/13/2025 (Estimated)RLAYRelay Therapeutics-$341.97M-$2.39N/AN/AN/AN/A-45.75%-40.75%5/5/2025 (Estimated)VALNValneva-$109.78M-$0.17N/AN/AN/A-4.35%-3.93%-1.42%5/6/2025 (Estimated)Latest OGI, COGT, RLAY, and VALN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025OGIOrganigram-$0.03N/AN/AN/A$61.27 millionN/A5/6/2025Q1 2025COGTCogent Biosciences-$0.55N/AN/AN/AN/AN/A5/6/2025Q1 2025VALNValneva-$0.40N/AN/AN/A$41.80 millionN/A5/5/2025Q1 2025RLAYRelay Therapeutics-$0.51N/AN/AN/A$0.01 millionN/A3/20/2025Q4 2024VALNValneva-$0.22-$0.54-$0.32-$0.54$55.64 million$56.48 million2/26/2025Q4 2024RLAYRelay Therapeutics-$0.57-$0.45+$0.12-$0.45$5.53 millionN/A2/11/2025Q1 2025OGIOrganigram-$0.03-$0.05-$0.02-$0.14$48.94 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/AOGIOrganigramN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent BiosciencesN/A6.446.44OGIOrganigramN/A3.361.85RLAYRelay TherapeuticsN/A18.4218.42VALNValneva0.702.782.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/AOGIOrganigram34.63%RLAYRelay Therapeutics96.98%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences5.92%OGIOrganigram0.09%RLAYRelay Therapeutics4.32%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80113.86 million103.92 millionOptionableOGIOrganigram860126.27 million126.10 millionOptionableRLAYRelay Therapeutics330169.52 million160.15 millionOptionableVALNValneva70083.64 million69.15 millionNot OptionableOGI, COGT, RLAY, and VALN HeadlinesRecent News About These CompaniesShort Interest in Valneva SE (NASDAQ:VALN) Drops By 49.2%April 29 at 3:02 AM | marketbeat.comValneva’s chikungunya vaccine roll-out hit by French authoritiesApril 28 at 9:44 PM | thepharmaletter.comFrance probes side effects with Valneva's chikungunya jabApril 28 at 9:44 PM | pharmaphorum.comFrench health authorities suspend use of Valneva's chikungunya vaccine in older adults to probe 3 hospitalizations, one deathApril 28 at 9:44 PM | fiercepharma.comFrance halts Valneva’s chikungunya vaccine use in seniorsApril 28 at 9:44 PM | finance.yahoo.comValneva Shares Slump After France Suspends Chikungunya Vaccine for ElderlyApril 28 at 5:35 AM | marketwatch.comIn a world first, Brazil approves chikungunya vaccineApril 28 at 12:35 AM | msn.comValneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French AuthoritiesApril 26 at 1:10 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 25, 2025 | globenewswire.comValneva (NASDAQ:VALN) Shares Gap Up - Still a Buy?April 24, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 24, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 21, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 20, 2025 | accessnewswire.comHead to Head Comparison: Valneva (NASDAQ:VALN) & enGene (NASDAQ:ENGN)April 20, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 18, 2025 | accessnewswire.comValneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. TravelersApril 18, 2025 | globenewswire.comCDC advisers update recommendations for meningococcal, RSV, chikungunya vaccinesApril 18, 2025 | cidrap.umn.eduVaccine advisory panel recommends expanded RSV use, and two new vaccinesApril 18, 2025 | statnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 17, 2025 | gurufocus.comValneva (NASDAQ:VALN) Receives "Buy" Rating from HC WainwrightApril 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThese 3 Stocks Have Huge Last 12 Months Shareholder YieldsBy Leo Miller | April 18, 2025View These 3 Stocks Have Huge Last 12 Months Shareholder Yields3 High-Value Companies With Triple-Digit Upside PotentialBy Nathan Reiff | April 16, 2025View 3 High-Value Companies With Triple-Digit Upside PotentialWhy Uber’s Stock Could Soar on AV Growth and Tariff ResilienceBy Jea Yu | April 16, 2025View Why Uber’s Stock Could Soar on AV Growth and Tariff ResilienceAI Arms Race: U.S. vs China—These 4 Stocks Stand OutBy Jea Yu | April 4, 2025View AI Arms Race: U.S. vs China—These 4 Stocks Stand OutAmprius Market Gets Amped Up on Growth OutlookBy Thomas Hughes | April 1, 2025View Amprius Market Gets Amped Up on Growth OutlookOGI, COGT, RLAY, and VALN Company DescriptionsCogent Biosciences NASDAQ:COGT$5.02 +0.11 (+2.24%) Closing price 04:00 PM EasternExtended Trading$5.03 +0.01 (+0.20%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Organigram NASDAQ:OGI$1.14 +0.02 (+1.79%) Closing price 04:00 PM EasternExtended Trading$1.12 -0.02 (-1.75%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Relay Therapeutics NASDAQ:RLAY$3.10 -0.16 (-4.91%) Closing price 04:00 PM EasternExtended Trading$3.06 -0.04 (-1.29%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Valneva NASDAQ:VALN$6.46 -0.12 (-1.75%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
